{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:44:59Z","timestamp":1791773099298,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd013524","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000}}],"reference-count":103,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013524.pub2","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:22:09Z","timestamp":1767961329000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cladribine for people with multiple sclerosis"],"prefix":"10.1002","volume":"2026","author":[{"given":"Maria Grazia","family":"Celani","sequence":"additional","affiliation":[{"name":"Dpt of Neurophysiopathology; Perugia General Hospital; Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-1202","authenticated-orcid":false,"given":"Massimiliano","family":"Orso","sequence":"additional","affiliation":[{"name":"Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche \"Togo Rosati\"; Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-4125","authenticated-orcid":false,"given":"Marta","family":"Melis","sequence":"additional","affiliation":[{"name":"Dpt of Neurology; Policlinico Duilio Casula, AOU Monserrato; Cagliari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-350X","authenticated-orcid":false,"given":"Maria Vittoria","family":"Ercolani","sequence":"additional","affiliation":[{"name":"Centro Speranza; Fratta Todina, Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-7718","authenticated-orcid":false,"given":"Teresa Anna","family":"Cantisani","sequence":"additional","affiliation":[{"name":"Cochrane Neurological Sciences Field; Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD013524.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/1744666X.2016.1191351","article-title":"Further understanding of the immunopathology of multiple sclerosis: impact on future treatments","volume":"12","author":"Bhise","year":"2016","journal-title":"Expert Review of Clinical Immunology"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1\u201316","DOI":"10.1177\/17562864211007687","article-title":"Inflammation in multiple sclerosis","volume":"14","author":"Haase","year":"2021","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"11","key":"10.1002\/14651858.CD013524.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4103\/1673-5374.194804","article-title":"Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response","volume":"11","author":"Koudriavtseva","year":"2016","journal-title":"Neural Regeneration Research"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.wco.0000413319.87092.19","article-title":"Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs","volume":"25 Suppl","author":"Miller","year":"2012","journal-title":"Current Opinion in Neurology"},{"issue":"10","key":"10.1002\/14651858.CD013524.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"14","key":"10.1002\/14651858.CD013524.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Multiple Sclerosis"},{"issue":"7","key":"10.1002\/14651858.CD013524.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(21)00170-8","article-title":"Multiple sclerosis under the spotlight","volume":"20","author":"Atlas of","year":"2021","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Multiple Sclerosis Collaborators","year":"2019","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013524.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"e210153","DOI":"10.1212\/WNL.0000000000210153","article-title":"Utility of progression independent of relapse activity as a trial outcome in relapsing-remitting multiple sclerosis","volume":"104","author":"Strijbis","year":"2025","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ana.24241","article-title":"Spinal cord gray matter atrophy correlates with multiple sclerosis disability","volume":"76","author":"Schlaeger","year":"2014","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013524.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1474-4422(22)00255-1","article-title":"Genetics of multiple sclerosis: lessons from polygenicity","volume":"21","author":"Goris","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006264.pub2","article-title":"Corticosteroids for the long-term treatment in multiple sclerosis","author":"Ciccone","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/cei.13473","article-title":"Cladribine modifies functional properties of microglia","volume":"201","author":"Hyrlov","year":"2020","journal-title":"Clinical and Experimental Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e0129182","DOI":"10.1371\/journal.pone.0129182","article-title":"Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells","volume":"10","author":"Korsen","year":"2015","journal-title":"PLOS One"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0022|cit22","first-page":"S45","article-title":"Preferential effects of cladribine on lymphocyte subpopulations","volume":"14","author":"Guarnaccia","year":"2008","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/ijms24044067","article-title":"Serum neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting","volume":"24","author":"Seiberl","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD013524.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1996.14.7.2160","article-title":"Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia","volume":"14","author":"Juliusson","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"8825","key":"10.1002\/14651858.CD013524.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8914","key":"10.1002\/14651858.CD013524.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"McMillan","year":"1994","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013524.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1525-1381.1999.09115.x","article-title":"A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis","volume":"111","author":"Romine","year":"1999","journal-title":"Proceedings of the Association of American Physicians"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/1352458509103610","article-title":"Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study","volume":"15","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013524.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013524.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"e:477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: the ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurology Neuroimmunology and Neuroinflammation"},{"issue":"5","key":"10.1002\/14651858.CD013524.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: the ONWARD study","volume":"5","author":"\u00a0Cohen","year":"2018","journal-title":"Neurology Neuroimmunology and Neuroinflammation"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0037|cit37","unstructured":"European Medicines Agency European Commission grants approval for Mavenclad (cladribine tablets) https:\/\/www.merckgroup.com\/en\/news\/mavenclad-25-08-2017.html"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0038|cit38","unstructured":"FDA approves new oral treatment for multiple sclerosis https:\/\/www.prnewswire.com\/news-releases\/fda-approves-new-oral-treatment-for-multiple-sclerosis-300821270.html"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0039|cit39","unstructured":"European Medicines Agency Withdrawal assessment report for Movectro EMA\/CHMP\/351065\/2010 https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-movectro_en.pdf"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"12","key":"10.1002\/14651858.CD013524.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"102572","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1002\/14651858.CD013524.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"14 Supplement","key":"10.1002\/14651858.CD013524.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"P7.011","DOI":"10.1212\/WNL.84.14_supplement.P7.011","article-title":"Cancer risk is not increased in people with relapsing multiple sclerosis taking cladribine","volume":"84","author":"Pakpoor","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0045|cit45","unstructured":"World Health Organization WHO Essential Medicines for Multiple Sclerosis; July 2023 https:\/\/www.who.int\/news\/item\/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosis"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013524.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013524.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0050|cit50","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0051|cit51","unstructured":"European Medicines Agency Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis-revision-2_en.pdf"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2011.08.001","article-title":"Disease activity free status in MS","volume":"1","author":"Lublin","year":"2012","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"10.1002\/14651858.CD013524.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","article-title":"Assessing 'no evidence of disease activity' status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the multiple sclerosis clinical and magnetic resonance imaging outcomes in the USA (MS-MRIUS) Study","volume":"32","author":"Weinstock-Guttman","year":"2018","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1002\/14651858.CD013524.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/135245850100700409","article-title":"The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice","volume":"7","author":"Boringa","year":"2001","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1076\/clin.16.3.381.13859","article-title":"Minimal neuropsychological assessment of MS patients: a consensus approach","volume":"16","author":"Benedict","year":"2002","journal-title":"Clinical Neuropsychologist"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"1-2","key":"10.1002\/14651858.CD013524.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2014.03.009","article-title":"Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial","volume":"340","author":"Erlanger","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","article-title":"Cognition in multiple sclerosis: state of the field and priorities for the future","volume":"90","author":"Sumowski","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.msard.2019.01.055","article-title":"Depressive symptoms and fatigue as predictors of objective-subjective discrepancies in cognitive function in multiple sclerosis","volume":"30","author":"Hughes","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"12","key":"10.1002\/14651858.CD013524.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1177\/1352458509347150","article-title":"Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients","volume":"15","author":"Honarmand","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"10.1002\/14651858.CD013524.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29)\u2014a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1191\/026921501673658108","article-title":"Developing a disease-specific quality of life measure for people with multiple sclerosis","volume":"15","author":"Ford","year":"2001","journal-title":"Clinical Rehabilitation"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0068|cit68","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0070|cit70","unstructured":"Excel tool to implement RoB 2; 22 August 2019 https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013524","article-title":"Cladribine for people with multiple sclerosis","author":"Celani","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0073|cit73","unstructured":"Sterne JA Egger M Moher D Boutron I Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0075|cit75","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, at al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0076|cit76","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0077|cit77","unstructured":"Melis M Raw data for meta-analyses [personal communication] Email to: Tomas Kalincik"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0078|cit78","unstructured":"Celani MG Raw data for meta-analyses [personal communication] Email to: Merck (ResponsibleDatasharing@merckgroup.com)"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0079|cit79","unstructured":"Orso M Raw data for meta-analyses [personal communication] Email to: Tomas Kalincik"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0080|cit80","unstructured":"Orso M Raw data for meta-analyses [personal communication] Email to: Izanne Roos"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0081|cit81","unstructured":"Celani MG Raw data for meta-analyses [personal communication] Email to: Juan I. Rojas"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0082|cit82","unstructured":"Orso M Raw data for meta-analyses [personal communication] Second email to: Juan I Rojas"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0083|cit83","unstructured":"Orso M Raw data for meta-analyses [personal communication] Email to: Tim Spelman"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0084|cit84","unstructured":"Orso M Raw data for meta-analyses [personal communication] Second email to: Tim Spelman"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0085|cit85","unstructured":"Orso M Raw data for meta-analyses [personal communication] Email to: Gavin Giovannoni"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0086|cit86","first-page":"93","article-title":"Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis","volume":"7","author":"\u00a0Kondera-Anasz","year":"2001","journal-title":"Medical Sciences Monitor"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"719-30","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD013524.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/13524585241302170","article-title":"Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: findings for the ORACLE-MS cohort","volume":"31","author":"Giovannoni","year":"2025","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD013524.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurology"},{"issue":"12","key":"10.1002\/14651858.CD013524.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1177\/1352458517728812","article-title":"Cladribine versus fingolimod, natalizumab and interferon \u03b2 for multiple sclerosis","volume":"24","author":"Kalincik","year":"2018","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD013524.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry","volume":"29","author":"Spelman","year":"2023","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0092|cit92","unstructured":"Cladribine to halt deterioration in people with advanced multiple sclerosis (ChariotMS) https:\/\/clinicaltrials.gov\/study\/NCT04695080"},{"issue":"7","key":"10.1002\/14651858.CD013524.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"1167\u201376","DOI":"10.1080\/03007995.2022.2059977","article-title":"The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets","volume":"38","author":"Butzkueven","year":"2022","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0094|cit94","unstructured":"Cladribine vs placebo for non-active progressive multiple sclerosis (CLASP-MS) https:\/\/clinicaltrials.gov\/study\/NCT05961644"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864241310996","article-title":"A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update","volume":"18","author":"Hellwig","year":"2025","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0096|cit96","unstructured":"Norwegian study of Oral cladribine versus Rituximab in Multiple Sclerosis (NOR-MS). A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study https:\/\/clinicaltrials.gov\/study\/NCT04121403"},{"issue":"6","key":"10.1002\/14651858.CD013524.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0098|cit98","unstructured":"Celani MG Request for full-text article [personal communication] Email to: Biblioteca Biomedica (biblioteca.medc.dd@unipg.it)"},{"issue":"8","key":"10.1002\/14651858.CD013524.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing\u2013remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"104459","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Multiple Sclerosis Related Disorders"},{"issue":"9","key":"10.1002\/14651858.CD013524.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s10072-023-06794-w","article-title":"Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis","volume":"44","author":"Nabizadeh","year":"2023","journal-title":"Neurological Sciences"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40264-020-00948-x","article-title":"Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety","volume":"43","author":"Giovannoni","year":"2020","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD013524.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"851413","DOI":"10.3389\/fneur.2022.851413.","article-title":"Modifying drugs and breastfeeding in multiple sclerosis: a narrative literature review","volume":"13","author":"Capone","year":"2022","journal-title":"Frontiers in Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:03:59Z","timestamp":1791770639000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013524.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013524.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}